Kisqali (ribociclib) is one of three CDK4/6 inhibitors that have changed treatment for hormone receptor positive, HER2 negative breast cancer, the most common type. It is taken by mouth together with hormone therapy, first for metastatic disease and, since September 2024, also for early breast cancer at high risk of coming back. Because it is taken for months or years, its side effects matter as much as its benefits. This guide explains what the official prescribing information reports, which side effects are common and which need attention, why Kisqali comes with regular blood tests and heart checks, how it differs from Verzenio and Ibrance, and what happens when it stops working, the point at which many people start looking at clinical trials.
Breast cancer progressing on Kisqali, Verzenio, or Ibrance?
Many studies are testing what comes next for hormone receptor positive breast cancer after a CDK4/6 inhibitor.
What Kisqali does
Cancer cells need to divide to grow, and CDK4 and CDK6 are enzymes that help push a cell through division. Kisqali blocks them, which slows the growth of hormone receptor positive cancer cells, and it is always combined with hormone therapy: an aromatase inhibitor in early breast cancer, and an aromatase inhibitor or fulvestrant in metastatic disease. In metastatic breast cancer it is a standard first treatment. In early breast cancer, the trial behind the 2024 approval showed that adding Kisqali to hormone therapy reduced the risk of the cancer returning by about a quarter in people with stage II and III disease at high risk of recurrence.
Our breast cancer treatment guide puts it in context with other options.
The most common side effects
Low white blood cells (neutropenia). This is by far the most common effect, and mostly it is found on blood tests rather than felt. In the early breast cancer trial, 94 percent of people had a drop in neutrophils, including 45 percent with a severe drop, yet fever with low white cells, the dangerous form, occurred in only 0.3 percent. It usually appears within the first weeks; the label reports a median of 18 days to a moderate drop. This is why blood counts are checked regularly and why doses are sometimes paused or reduced.
Infections, nausea, fatigue, and headache. These were the most common side effects in early breast cancer. In metastatic breast cancer, where Kisqali is used at a higher dose, the list also includes diarrhea, vomiting, constipation, hair thinning, cough, rash, and back pain. Across the metastatic trials, infections and nausea each affected about 47 percent of people, fatigue 35 percent, and diarrhea 33 percent.
Why your heart and liver are checked
QT prolongation. Kisqali can lengthen the QT interval, a measure of the heart's electrical cycle, which in rare cases can lead to dangerous rhythms. That is why an ECG is done before starting and in the first weeks of treatment, electrolytes are checked, and certain other medicines that also affect the QT interval are avoided. In the early breast cancer trial, a large QT increase was uncommon: about 2 percent had an increase of more than 60 milliseconds, and 0.3 percent reached a QT above 500 milliseconds. Palpitations, fainting, or dizziness should be reported right away.
Liver effects. Raised liver enzymes are common, which is why liver tests are part of routine monitoring. Yellowing of the skin or eyes, dark urine, or pain in the upper right abdomen need prompt attention.
Lung inflammation and severe skin reactions. Rarely, CDK4/6 inhibitors cause inflammation of the lungs (interstitial lung disease or pneumonitis), reported in 1.5 percent in the early breast cancer trial, mostly mild. Severe skin reactions are very rare. New cough or breathlessness, or a spreading or blistering rash, should be reported immediately.
Kisqali vs Verzenio vs Ibrance
All three CDK4/6 inhibitors work the same way and are used in similar situations, but their side effect profiles differ in ways that often shape the choice. Kisqali is the one that needs heart rhythm monitoring and liver checks. Verzenio (abemaciclib) is best known for diarrhea, especially early on, and causes less severe neutropenia. Ibrance (palbociclib) is mainly associated with neutropenia and fatigue, with fewer digestive problems. Kisqali and Verzenio are approved for high risk early breast cancer as well as metastatic disease, while Ibrance is used in metastatic disease. If one does not suit you, switching to another is sometimes possible, and your oncologist will weigh your other medicines and health conditions.
Living with Kisqali day to day
Most people take Kisqali in cycles, three weeks on and one week off, which gives blood counts time to recover. Practical steps that help: keep every blood test and ECG appointment, report fever promptly because low white cells make infections more serious, check with your pharmacist before starting any new medicine or supplement, and avoid grapefruit, which can raise Kisqali levels. Many side effects are managed by pausing or lowering the dose rather than stopping, so tell your care team early rather than pushing through. Never change the dose yourself.
When Kisqali stops working
In metastatic breast cancer, CDK4/6 inhibitors often control the disease for a long time, but for most people the cancer eventually finds a way around them, a moment known as progression. What comes next depends on the cancer's biology, which is why doctors often test the tumor or blood for changes such as ESR1, PIK3CA, AKT1, or PTEN mutations. Options include newer hormone therapies, targeted pills matched to those mutations, antibody drug conjugates, and chemotherapy. This point, after progression on a CDK4/6 inhibitor, is also one of the most active areas of breast cancer research: many current studies enroll people exactly at this step, testing new hormone therapies, new targeted combinations, and next generation CDK inhibitors. Our metastatic breast cancer clinical trials page lists studies recruiting now.
How to find a breast cancer study
AllClinicalTrials.com lists breast cancer studies recruiting across the US and Canada, and you can filter by location and phase. Studies for hormone receptor positive breast cancer include trials for early breast cancer at high risk of recurrence and many trials for metastatic disease, including after progression on Kisqali, Verzenio, or Ibrance; see our breast cancer clinical trials and metastatic breast cancer clinical trials pages. The application takes about 5 minutes: you answer questions about your diagnosis, treatments, and current health, and if a study near you looks like a match, the research team contacts you. Nothing is decided until you have gone through informed consent, and participation is voluntary at every step.
Three things to have ready: your cancer type (for example HR positive, HER2 negative) and stage, the treatments you have had and when, and any genetic or biomarker test results such as ESR1 or PIK3CA.
Common questions
What are the most common side effects of Kisqali? Low white blood cell counts, infections, nausea, fatigue, and headache, plus diarrhea, vomiting, constipation, hair thinning, cough, rash, and back pain in metastatic breast cancer.
Why do I need ECGs on Kisqali? Because Kisqali can lengthen the QT interval of the heartbeat. An ECG is done before treatment and in the first weeks to catch this early, and some medicines that affect the QT interval are avoided.
Does Kisqali cause hair loss? Hair thinning is reported more often in metastatic breast cancer, where it affected between about 19 and 33 percent of people, depending on the trial. It is usually milder than with chemotherapy.
Is Kisqali used for early breast cancer? Yes. Since September 2024 it is approved with an aromatase inhibitor for HR positive, HER2 negative stage II and III breast cancer at high risk of recurrence, where it reduced the risk of recurrence by about a quarter.
Is Kisqali or Verzenio easier to tolerate? It depends on the person. Verzenio more often causes diarrhea, while Kisqali needs heart and liver monitoring and more often lowers white cells. Your oncologist weighs these against your health and other medicines.
What happens when Kisqali stops working? Doctors usually test for tumor mutations and choose among newer hormone therapies, targeted pills, antibody drug conjugates, or chemotherapy. Many clinical trials enroll people at exactly this point.
Can I join a trial while on Kisqali? Some studies enroll people currently on a CDK4/6 inhibitor, while many enroll people after it stops working. Each study lists its rules.
Do breast cancer trial participants get paid? Some studies offer compensation for time and travel, and study related care is typically provided at no cost to participants. Compensation varies by trial and is always described during the informed consent process before you agree to anything.
See breast cancer clinical trials recruiting now
Browse open studies, filter by location, and apply in about 5 minutes: Breast Cancer Clinical Trials.